Novel Insights into the Physiological and Pathological Role of Leptin and Leptin Receptor
A special issue of Receptors (ISSN 2813-2564).
Deadline for manuscript submissions: closed (31 July 2023) | Viewed by 181
Special Issue Editors
Interests: breast cancer; glioblastoma; seminoma; obesity; leptin; aromatase
Special Issues, Collections and Topics in MDPI journals
Interests: breast cancer; tumor microenvironment; adipokines; nuclear receptors; ESR1 mutations; endocrine-resistance; exosomes
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
In recent years, research efforts have been expanded to clarify the role of leptin/leptin receptors in human physiology and in the pathophysiology of several disorders. However, more studies are needed to fully elucidate leptin/leptin receptor signaling pathways. The adipocyte-derived factor leptin and its receptor (ObR) are widely expressed in a large spectrum of tissues, wherein they play a pivotal role in energy homeostasis, metabolism, and in neuroendocrine and immune functions. Further, it has been demonstrated that the leptin/leptin receptor signaling pathway is linked to the proliferation, migration, and invasion of cancer cells. Indeed, targeting the leptin/leptin receptor has generated a great amount of interest in the design and development of several modulators that could offer a valuable therapeutic strategy in many diseases.
In this Special Issue, we welcome original research articles, as well as review articles, in order to provide new knowledge about the physiological and pathological significance of leptin/leptin receptors.
You may choose our Joint Special Issue in Biomolecules.
Dr. Salvatore Panza
Dr. Luca Gelsomino
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Receptors is an international peer-reviewed open access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- leptin
- leptin receptor
- metabolic disorders
- obesity
- cancer
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.